Intestinal strongyloidiasis: Recognition, management, and determinants of outcome

Journal of Clinical Gastroenterology

Volumn 39, Issue 3, 2005, Pages 203-211

  Concha, Ronald ^a   Harrington Jr , William ^a   Rogers, Arvey I ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b NONE   (United States)

Author keywords

Diagnosis; Host immune competence; Intestinal strongyloidiasis; Risk factors; Treatment

Indexed keywords

ALBENDAZOLE; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; IVERMECTIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; PROCARBAZINE; RUFOCROMOMYCIN; TIABENDAZOLE; VINBLASTINE;

ABDOMINAL PAIN; ACHLORHYDRIA; ALCOHOLISM; CLINICAL FEATURE; CYTOKINE RELEASE; DISEASE SEVERITY; DIZZINESS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUSHING; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE INFECTION; KIDNEY TRANSPLANTATION; LEPROMATOUS LEPROSY; LUNG INFECTION; LYMPHOMA; MALAISE; NAUSEA AND VOMITING; NONHUMAN; PARESTHESIA; PRIORITY JOURNAL; PROTEIN CALORIE MALNUTRITION; PRURITUS; RADIOTHERAPY; REVIEW; RISK FACTOR; STOMACH MOTILITY; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; TH2 CELL; VIRUS INFECTION; WESTERN BLOTTING;

HUMANS; INTESTINAL DISEASES, PARASITIC; RISK FACTORS; STRONGYLOIDIASIS;

EID: 14144250830     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000152779.68900.33     Document Type: Review

References (136)

1. Genta RM. Global prevalence of strongyloidiasis: critical review with epidemiologic insights into the prevention of disseminated disease. Rev Infect Dis. 1989;11:755-767.
2. Bannon JP, Fater M, Solit R. Intestinal ileus secondary to Strongyloides stercoralis infection: case report and review of the literature. Am Surg. 1995;61:377-380.
3. Scowden EB, Schaffner W, Stone WJ. Overwhelming strongyloidiasis: an unappreciated opportunistic infection. Medicine (Baltimore). 1978;57:527-544.
4. Igra-Siegman Y, Kapila R, Sen P, et al. Syndrome of hyperinfection with Strongyloides stercoralis. Rev Infect Dis. 1981;3:397-407.
5. Purtilo DT, Meyers WM, Connor DH. Fatal strongyloidiasis in immunosuppressed patients. Am J Med. 1974;56:488-493.
6. Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic enteric infections: a perspective. Ann Intern Med. 1973;78:271-276.
7. Genta RM, Miles P, Fields K. Opportunistic Strongyloides stercoralis infection in lymphoma patients: report of a case and review of the literature. Cancer. 1989;63:1407-1411.
8. Nucci M, Portugal R, Pulcheri W, et al. Strongyloidiasis in patients with hematological malignancies. Clin Infect Dis. 1995;21:675-677.
9. Yee A, Boylen CT, Noguchi T, et al. Fatal Strongyloides stercoralis infection in a patient receiving corticosteroids. West J Med. 1987;146:363-364.
10. Simpson WG, Gerhardstein DC, Thompson JR. Disseminated Strongyloides stercoralis infection. South Med J. 1993;86:821-825.
11. Wang BY, Krishnan S, Isenberg HD. Mortality associated with concurrent strongyloidosis and cytomegalovirus infection in a patient on steroid therapy. Mt Sinai J Med. 1999;66:128-132.
12. Kaslow JE, Novey HS, Zuch RH, et al. Disseminated strongyloidiasis: an unheralded risk of corticosteroid therapy. J Allergy Clin Immunol. 1990;86:138.
13. Leung VK, Liew CT, Sung JJ. Fatal strongyloidiasis in a patient with ulcerative colitis after corticosteroid therapy. Am J Gastroenterol. 1997;92:1383-1384.
14. Kebede D. Strongyloidiasis and glucocorticoids: case report. Va Med. 1986;113:104-105.
15. Kim YK, Kim H, Park YC, et al. A case of hyperinfection with Strongyloides stercoralis in an immunosuppressed patient. Korean J Intern Med. 1989;4:165-170.
16. Morgan JS, Schaffner W, Stone WJ. Opportunistic strongyloidiasis in renal transplant recipients. Transplantation. 1986;42:518-524.
17. Hoy WE, Roberts NJ Jr, Bryson MF, et al. Transmission of strongyloidiasis by kidney transplant? Disseminated strongyloidiasis in both recipients of kidney allografts from a single cadaver donor. JAMA. 1981;246:1937-1939.
18. Palau LA, Pankey GA. Strongyloides hyperinfection in a renal transplant recipient receiving cyclosporine: possible Strongyloides stercoralis transmission by kidney transplant. Am J Trop Med Hyg. 1997;57:413-415.
19. Morris A, Van der Merwe W, Simpson I. Fatal strongyloidiasis in a renal transplant patient. N Z Med J. 1987;100:427.
20. Vishwanath S, Baker RA, Mansheim BJ. Strongyloides infection and meningitis in an immunocompromised host. Am J Trop Med Hyg. 1982;31:857-858.
21. German JC, Flores JH, Chiesura G, et al. Fatal strongyloidiasis in an immunodepressed patient following renal transplantation. Rev Hosp Clin Fac Med Sao Paulo. 1992;47:31-33.
22. Narasimhan N, Piering WF, Kauffman HM, et al. Kidney transplant recipient with disseminated Strongyloides. Transplantation. 1983;36:472-473.
23. De Vault GA Jr, Brown ST 3rd, Montoya SF Jr, et al. Disseminated strongyloidiasis complicating acute renal allograft rejection: prolonged thiabendazole administration and successful retransplantation. Transplantation. 1982;34:220-221.
24. Hirschmann JV, Plorde JJ, Ochi RF. Fever and pulmonary infiltrates in a patient with a renal transplant. West J Med. 1984;140:914-920.
25. Scoggin CH, Call NB. Acute respiratory failure due to disseminated strongyloidiasis in a renal transplant recipient. Ann Intern Med. 1977;87:456-458.
26. Gotuzzo E, Terashima A, Alvarez H, et al. Strongyloides stercoralis hyperinfection associated with human T cell lymphotropic virus type-1 infection in Peru. Am J Trop Med Hyg. 1999;60:146-149.
27. Gotuzzo E, Arango C, de Queiroz-Campos A, et al. Human T-cell lymphotropic virus-I in Latin America. Infect Dis Clin North Am. 2000;14:211-239.
28. Compels MM, Todd J, Peters BS, et al. Disseminated strongyloidiasis in AIDS: uncommon but important. AIDS. 1991;5:329-332.
29. Harcourt-Webster JN, Scaravilli F, Darwish AH. Strongyloides stercoralis hyperinfection in an HIV positive patient. J Clin Pathol. 1991;44:346-348.
30. Nomura J, Rekrut K. Strongyloides stercoralis hyperinfection syndrome in a patient with AIDS: diagnosis by fluorescent microscopy. Clin Infect Dis. 1996;22:736.
31. Cirioni O, Giacometti A, Burzacchini F, et al. Strongyloides stercoralis first-stage larvae in the lungs of a patient with AIDS: primary localization or a noninvasive form of dissemination? Clin Infect Dis. 1996;22:737.
32. Kao D, Murakawa GJ, Kerschmann R, et al. Disseminated strongyloidiasis in a patient with acquired immunodeficiency syndrome. Arch Dermatol. 1996;132:977-978.
33. Makris AN, Sher S, Bertoli C, et al. Pulmonary strongyloidiasis: an unusual opportunistic pneumonia in a patient with AIDS. AJR Am J Roentgenol. 1993;161:545-547.
34. Ferreira MS, Nishioka Sde A, Borges AS, et al. Strongyloidiasis and infection due to human immunodeficiency virus: 25 cases at a Brazilian teaching hospital, including seven cases of hyperinfection syndrome. Clin Infect Dis. 1999;28:154-155.
35. Maayan S, Wormser GP, Widerhorn J, et al. Strongyloides stercoralis hyperinfection in a patient with the acquired immune deficiency syndrome. Am J Med. 1987;83:945-948.
36. Vieyra-Herrera G, Becerril-Carmona G, Padua-Gabriel A, et al. Strongyloides stercoralis hyperinfection in a patient with the acquired immune deficiency syndrome. Acta Cytol. 1988;32:277-278.
37. Lessnau KD, Can S, Talavera W. Disseminated Strongyloides stercoralis in human immunodeficiency virus-infected patients: treatment failure and a review of the literature. Chest. 1993;104:119-122.
38. Shelhamer JH, Neva FA, Finn DR. Persistent strongyloidiasis in an immunodeficient patient. Am J Trop Med Hyg. 1982;31:746-751.
39. Coovadia YM, Rajput MC, Bhana RH. Disseminated strongyloidiasis in a diabetic patient. Trop Geogr Med. 1993;45:179-180.
40. Grove DI. Strongyloidiasis: a conundrum for gastroenterologists. Gut. 1994;35:437-440.
41. Nonaka D, Takaki K, Tanaka M, et al. Paralytic ileus due to strongyloidiasis: case report and review of the literature. Am J Trop Med Hyg. 1998;59:535-538.
42. DeVault GA Jr, King JW, Rohr MS, et al. Opportunistic infections with Strongyloides stercoralis in renal transplantation. Rev Infect Dis. 1990;12:653-671.
43. Al-Bahrani ZR, Al-Saleem T, Al-Gailani MA. Sub-acute intestinal obstruction by Strongyloides stercoralis. J Infect. 1995;30:47-50.
44. Friedenberg F, Wongpraparut N, Fisher RA, et al. Duodenal obstruction caused by Strongyloides stercoralis enteritis in an HTLV-1-infected host. Dig Dis Sci. 1999;44:1184-1188.
45. Bhatt BD, Cappell MS, Smilow PC, et al. Recurrent massive upper gastrointestinal hemorrhage due to Strongyloides stercoralis infection. Am J Gastroenterol. 1990;85:1034-1036.
46. Brasitus TA, Gold RP, Kay RH, et al. Intestinal strongyloidiasis: a case report and review of the literature. Am J Gastroenterol. 1980;73:65-69.
47. Powell RW, Moss JP, Nagar D, et al. Strongyloidiasis in immunosuppressed hosts: presentation as massive lower gastrointestinal bleeding. Arch Intern Med. 1980;140:1061-1063.
48. Gutierrez Y, Bhatia P, Garbadawala ST, et al. Strongyloides stercoralis eosinophilic granulomatous enterocolitis. Am J Surg Pathol. 1996;20:603-612.
49. Al Samman M, Haque S, Long JD. Strongyloidiasis colitis: a case report and review of the literature. J Clin Gastroenterol. 1999;28:77-80.
50. Stoopack PM, Raufman JP. Aphthoid ulceration of the colon in Strongyloidiasis. Am J Gastroenterol. 1991;86:639-642.
51. Sen P, Gil C, Estrellas B, et al. Corticosteroid-induced asthma: a manifestation of limited hyperinfection syndrome due to Strongyloides stercoralis. South Med J. 1995;88:923-927.
52. Mahmoud AA. Strongyloidiasis. Clin Infect Dis. 1996;23:949-952.
53. Goyal SB. Intestinal Strongyloidiasis manifesting as eosinophilic pleural effusion. South Med J. 1998;91:768-769.
54. Oya H, Mon S, Tsuchihashi H, et al. A case of pleuritis caused by strongyloides in a carrier of T-cell lymphoma virus type I (HTLV-I). Nihon Kokyuki Gakkai Zasshi. 1998;36:262-267.
55. Setoyama M, Fukumaru S, Takasaki T, et al. SLE with death from acute massive pulmonary hemorrhage caused by disseminated Strongyloidiasis. Scand J Rheumatol. 1997;26:389-391.
56. Kothary NN, Muskie JM, Mathur SC. Strongyloides stercoralis hyperinfection. Radiographics. 1999;19:1077-1081.
57. Takayanagui OM, Lofrano MM, Araugo MB, et al. Detection of Strongyloides stercoralis in the cerebrospinal fluid of a patient with acquired immunodeficiency syndrome. Neurology. 1995;45:193-194.
58. Dutcher JP, Marcus SL, Tanowitz HB, et al. Disseminated Strongyloidiasis with central nervous system involvement diagnosed antemortem in a patient with acquired immunodeficiency syndrome and Burkitt's lymphoma. Cancer. 1990;66:2417-2420.
59. Link K, Orenstein R. Bacterial complications of strongyloidiasis: Streptococcus bovis meningitis. South Med J. 1999;92:728-731.
60. Schneider JH, Rogers AI. Strongyloidiasis: the protean parasitic infection. Postgrad Med. 1997;102:177-184.
61. Carvalho EM, Andrade TM, Andrade JA, et al. Immunological features in different clinical forms of Strongyloidiasis. Trans R Soc Trop Med Hyg. 1983;77:346-349.
62. Bodey GP, Fainstein V. Infection of the gastrointestinal tract in the immunocompromised patient. Annu Rev Med. 1986;37:271-281.
63. th ed. Rhahway, NJ: Merk Research Laboratories, 1999:1237-1275.
64. Kramer MR, Gregg PA, Goldstein M, et al. Disseminated strongyloidiasis in AIDS and non-AIDS immunocompromised hosts: diagnosis by sputum and bronchoalveolar lavage. South Med J. 1990;83:1226-1229.
65. Uparanukraw P, Phongsri S, Morakote N. Fluctuations of larval excretion in Strongyloides stercoralis infection. Am J Trop Med Hyg. 1999;60:967-973.
66. Neva FA, Gam AA, Maxcwell C, et al. Skin test antigens for immediate hypersensitivity prepared from infective larvae of Strongyloides stercoralis. Am J Trop Med Hyg. 2001;65:567-572.
67. th ed, vol. 5. London: Arnold, 1998:57-84.
68. Rotman HL, Yutanawiboonchai W, Brigandi RA, et al. Strongyloides stercoralis: eosinophil-dependent immune-mediated killing of third stage larvae in BALB/cByJ mice. Exp Parasitol. 1996;82:267-278.
69. Brigandi RA, Rotman HL, Yutanawiboonchai W, et al. Strongyloides stercoralis: role of antibody and complement in immunity to the third stage of larvae in BALB/cByJ mice. Exp Parasitol. 1996;82:279-289.
70. Taverne J, Bradley JE. Immunity to protozoa and worms. In: Roitt I, Brostoff J, Male D, eds. Immunology, 5th ed. London: Mosby, 1998:243-261.
71. Pritchard DI. The survival strategies of hookworms. Parasitol Today. 1995;11:255-259.
72. Urban JF Jr, Madden KB, Svetic A, et al. The importance of Th2 cytokines in protective immunity to nematodes. Immunol Rev. 1992;127:205-220.
73. Cox FE, Liew FY. T-cell subsets and cytokines in parasitic infections. Immunol Today. 1992;13:445-448.
74. Rotman HL, Schnyder-Candrian S, Scott P, et al. IL-12 eliminates the Th-2 dependent protective immune response of mice to larval Strongyloides stercoralis. Parasite Immunol. 1997;19:29-39.
75. Grencis RK. T cell and cytokine basis of host variability in response to intestinal nematode infections. Parasitology. 1996;112(suppl):31-37.
76. Locksley RM. Th2 cells: help for helminths. J Exp Med. 1994;179:1405-1407.
77. Sher A, Coffman RL. Regulation of immunity to parasites by T cells and T cell-derived cytokines. Annu Rev Immunol. 1992;10:385-409.
78. Finkelman FD, Holmes J, Katona IM, et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol. 1990;8:303-333.
79. Finkelman FD, Katona IM, Urban JF Jr, et al. IL-4 is required to generate and sustain in vivo IgE responses. J Immunol. 1988;141:2335-2341.
80. Miller HR, Huntley JF, Wallace GR. Immune exclusion and mucus trapping during the rapid expulsion of Nippostrongylus brasiliensis from primed rats. Immunology. 1981;44:419-429.
81. Trajman A, MacDonald TT, Elia CC. Intestinal immune cells in strongyloides stercoralis infection. J Clin Pathol. 1997;50:991-995.
82. Maruyama H, Yabu Y, Yoshida A, et al. A role of mast cell glycosaminoglycans for the immunological expulsion of intestinal nematode, strongyloides venezuelensis. J Immunol. 2000;164:3749-3754.
83. Barrett KE, Neva FA, Gam AA, et al. The immune response to nematode parasites: modulation of mast cell numbers and function during strongyloides stercoralis infections in nonhuman primates. Am J Trop Med Hyg. 1988;38:574-581.
84. Coffman RL, Seymour BW, Hudak S, et al. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science. 1989;245:308-310.
85. Korenaga M, Hitoshi Y, Yamaguchi N, et al. The role of interleukin-5 in protective immunity to Strongyloides venezuelensis infection in mice. Immunology. 1991;72:502-507.
86. Herbert DR, Lee JJ, Lee NA, et al. Role of IL-5 in innate and adaptive immunity to larval strongyloides stercoralis in mice. J Immunol. 2000;165:4544-4551.
87. Madden KB, Urban JF Jr, Ziltener HJ, et al. Antibodies to IL-3 and IL-4 suppress helminth induced intestinal mastocytosis. J Immunol. 1991;147:1387-1391.
88. Thompson-Snipes L, Dhar V, Bond MW, et al. Interleukin-10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med. 1991;173:507-510.
89. Wang CH, Korenaga M, Greenwood A, et al. T-helper subset function in the gut of rats: differential stimulation of eosinophils, mucosal mast cells and antibody-forming cells by OX8- OX22- and OX8- OX22+ cells. Immunology. 1990;71:166-175.
90. Ishikawa N, Shi BB, Khan AI, et al. Reserpine-induced sulphomucin production by goblet cells in the jejunum of rats and its significance in the establishment of intestinal helminths. Parasite Immunol. 1995;17:581-586.
91. Khan AI, Horii Y, Tiura R, et al. Mucosal mast cells and the expulsive mechanisms of mice against Strongyloides venezuelensis. Int J Parasitol. 1993;23:551-555.
92. Goldhill J, Morris SC, Maliszewski C, et al. Interleukin-4 modulates cholinergic neural control of mouse small intestinal longitudinal muscle. Am J Physiol. 1997;272:G1135-G1140.
93. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145-173.
94. Mosmann TR, Moore KW. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today. 1991;12:A49-A53.
95. Gajewski TF, Schell SR, Nau G, et al. Regulation of T cell activation: differences among T-cells subsets. Immunol Rev. 1989;111:79-110.
96. Urban JF, Madden KB, Cheever AW, et al. IFN inhibits inflammatory responses and protective immunity in mice infected with the nematode parasite, Nippostrongylus brasiliensis. J Immunol. 1993;151:7086-7094.
97. Corrigan CJ. Cellular effects of Glucocorticoids. Immunol Allergy Clin North Am. 1999;19:671-682.
98. Neva FA. Biology and immunology of human strongyloidiasis. J Infect Dis. 1986;153:397-406.
99. Mansfield LS, Niamatali S, Bhopale V, et al. Strongyloides stercoralis: maintenance of exceedingly chronic infections. Am J Trop Med Hyg. 1996;55:617-624.
100. Genta RM. Dysregulation of strongyloidiasis: a new hypothesis. Clin Microbiol Rev. 1992;5:345-355.
101. Aydin H, Doppl W, Battmann A, et al. Opportunistic strongyloides stercoralis hyperinfection in lymphoma patients undergoing chemotherapy and/or radiotherapy: report of a case and review of the literature. Acta Oncol. 1994;33:78-80.
102. Schad GA. Cyclosporine may eliminate the threat of overwhelming strongyloidiasis in immunosuppressed patients. J Infect Dis. 1986;153:178.
103. Armson A, Cunningham GA, Grubb WD, et al. Murine strongyloidiasis: the effects of cyclosporin A and thiabendazole administered singly and in combination. Int J Parasitol. 1995;25:533-535.
104. Nolan TJ, Schad GA. Tacrolimus allows autoinfective development of the parasitic nematode Strongyloides stercoralis. Transplantation. 1996;62:1038.
105. Ferreira OC Jr, Flanelles V, Rosenblatt JD. Human T-cell leukemia viruses: epidemiology, biology and pathogenesis. Blood Rev. 1997;11:91-104.
106. La Grenade L, Schwartz RA, Janniger CK. Childhood dermatitis in the tropics: with special emphasis on infective dermatitis, a marker for infection with human T-cell leukemia virus-I. Cutis. 1996;58:115-118.
107. La Grenade L. HTLV-1 associated infective dermatitis: past, present, and future. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13(suppl 1):46-49.
108. LaGrenade L, Hanchard B, Fletcher V, et al. Infective dermatitis of Jamaican children: a marker for HTLV-1 infection. Lancet. 1990;336:1345-1347.
109. Del Giudice P, Sainte Marie D, Gerard Y, et al. Is crusted (Norwegian) scabies a marker of adult T cell leukemia/lymphoma in human T lymphotropic virus type 1-seropositive patients? J Infect Dis. 1997;176:1090-1092.
110. Daisley H, Charles W, Suite M. Crusted (Norwegian) scabies as a prediagnostic indicator for HTLV-I infection. Trans R Soc Trop Med Hyg. 1993;87:295.
111. Mollison LC, Lo ST, Marning G. HTLV-I and scabies in Australian aborigines. Lancet. 1993;341:1281-1282.
112. Egawa K, Johno M, Hayashibara T, et al. Familiar occurrence of crusted (Norwegian) scabies with adult T-cell leukemia. Br J Dermatol. 1992;127:57-59.
113. Suzumiya J, Sumiyoshi A, Kuroki Y, et al. Crusted (Norwegian) scabies with adult T-cell leukemia. Arch Dermatol. 1985;121:903-904.
114. Verdier M, Denis F, Sangare A, et al. Prevalence of antibody to human T cell leukemia virus type I (HTLV-I) in populations of Ivory Coast, West Africa. J Infect Dis. 1989;160:363-370.
115. Kashala O, Marlink R, Ilunga M, et al. Infection with human immunodeficiency virus type I (HIV-I) and human T cell lymphotropic viruses among leprosy patients and contacts: correlation between HIV-I cross-reactivity and antibodies to lipoarabinomannan. J Infect Dis. 1994;169:296-304.
116. Marsh BJ. Infectious complications of human T cell leukemia/lymphoma virus type I infection. Clin Infect Dis. 1996;23:138-145.
117. Kanada S, Uematsu T, Iwahashi M, et al. The prevalence of human T-cell leukemia virus type I infection in patients with hematologie and nonhematologic diseases in an adult T-cell leukemia-endemic area of Japan. Cancer. 1989;64:1290-1295.
118. Nakada K, Kohakura M, Komoda H, et al. High incidence of HTLV antibody in carriers of Strongyloides stercoralis. Lancet. 1984;1:633.
119. Neva FA, Filho JO, Gam AA, et al. Interferon-gamma and interleukin-4 responses in relation to serum IgE levels in persons infected with human T lymphotropic virus type I and Strongyloides stercoralis. J Infect Dis. 1998;178:1856-1859.
120. Porto AF, Neva FA, Bittencourt H, et al. HTLV-I decreases Th2 type of immune response in patients with strongyloidiasis. Parasite Immunol. 2001;23:503-507.
121. Sato Y, Shiroma Y, Kiyuna S, et al. Reduced efficacy of chemotherapy might accumulate concurrent HTLV-I infection among strongyloidiasis patients in Okinawa, Japan. Trans R Soc Trop Med Hyg. 1994;88:59.
122. Centers for Disease Control. Update: acquired immunodeficiency syndrome (AIDS) in the United States. MMWR Morb Mortal Wkly Rep. 1982;31:507-508, 513-514.
123. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep. 1987;36(suppl 1):1-15.
124. Celedon JC, Mathur-Wagh U, Fox J, et al. Systemic strongyloidiasis in patients infected with the human immunodeficiency virus: a report of 3 cases and review of the literature. Medicine (Baltimore). 1994;73:256-263.
125. Cimerman S, Cimerman B, Lewi DS. Enteric parasites and AIDS. Sao Paulo Med J. 1999;117:266-273.
126. Tanaka M, Hirabayashi Y, Gatanaga H, et al. Reduction in interleukin-2-producing cells but not Th1 to Th2 shift in moderate and advanced stages of human immunodeficiency virus type-1-infection: direct analysis of intracellular cytokine concentrations in CD4+ CD8- T cells. Scand J Immunol. 1999;50:550-554.
127. Valdez H, Lederman MM. Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev. 1997;98:187-228.
128. Barker E, Mackewicz CE, Levy JA. Effects of TH1 and TH2 cytokines on CD8+ cell response against human immunodeficiency virus: implications for long-term survival. Proc Natl Acad Sci USA. 1995;92:11135-11139.
129. Culshaw RJ, Bancroft GJ, McDonald V. Gut intraepithelial lymphocytes induce immunity against Cryptosporidium infection through a mechanism involving gamma Interferon production. Infect Immun. 1997;65:3074-3079.
130. Leigh JE, Steele C, Wormley FL Jr, et al. Th1/Th2 cytokine expression in saliva of HIV-positive and HIV-negative individuals: a pilot study in HIV-positive individuals with oropharyngeal candidiasis. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:373-380.
131. Petithory JC, Derouin F. AIDS and strongyloidiasis in Africa. Lancet. 1987;1:921.
132. Archibald LK, Beeching NJ, Gill GV, et al. Albendazole is effective treatment for chronic Strongyloidiasis. Q J Med. 1993;86:191-195.
133. Boken DJ, Leoni PA, Preheim LC. Treatment of Strongyloides stercoralis hyperinfection syndrome with Thiabendazole administered per rectum. Clin Infect Dis. 1993;16:123-126.
134. Naquira C, Jimenez G, Guerra JG, et al. Ivermectin for human Strongyloidiasis and other intestinal helminths. Am J Trop Med Hyg. 1989;40:304-309.
135. Dairy A, Hilmarsdottir I, Mayorga-Sagastume R, et al. Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases. Trans R Soc Trop Med Hyg. 1994;88:344-345.
136. Torres JR, Isturiz R, Murillo J, et al. Efficacy of Ivermectin in the treatment of Strongyloidiasis complicating AIDS. Clin Infect Dis. 1993;17:900-902.